CNIM : Bertin Pharma, a subsidiary of Bertin Technologies, a CNIM Group entity, has entered into exclusive negotiations for the sale of its pharmaceutical and biotech services operations with two French specialist companies in that field.

Montigny-le-Bretonneux - 10 May 2017 - Following a competitive process, Bertin Pharma has entered into exclusive negotiations with Amatsigroup with a view to the sale of its pharmaceutical development operations (sites at Artigues-près-Bordeaux and Martillac) and with the Oncodesign group with a view to the sale of its pre-clinical and clinical research operations carried out at the other sites.

Through this proposed sale of services operations in the pharmaceuticals/biotech sector, the CNIM Group aims to focus on strategic areas which are more closely in line with its core industrial business in the fields of energy, the environment, defense and security. The quality and ambition of both purchasers also look set to boost the development prospects of the Bertin Pharma operations and teams involved.

The other staff working primarily on bioanalysis and biodefense tools will continue their work at Bertin Pharma, in close collaboration with the teams at Bertin Technologies.

This project, which is the subject of an information and consultation procedure with the representative bodies for the staff concerned, could be completed in summer 2017.

Bertin Pharma, with bases in the Ile de France, Centre and Aquitaine regions, had its origins in the consolidation of several companies created or acquired between 1999 and 2013 (Ellipse Pharmaceuticals, SPI-Bio, Biotec Centre, IDPS, Johnson&Johnson Santé Beauté France).

Bertin Pharma employs 125 staff and achieves revenues of €16 million.

BERTIN TECHNOLOGIES, subsidiary of CNIM Group, relies on its long history of innovation to develop, produce and market innovative systems and equipment worldwide. With close to €96M in revenues and 700 partners in 2016, of which 2/3rd are engineers and high-level managers, Bertin Technologies and its subsidiaries work in four major fields: Systems and Instrumentation, Consulting and Engineering, Information Technology and Pharmaceuticals and Biotechs. Based in the Paris region, the company is active worldwide.

The CNIM Group designs, develops and manufactures turnkey industrial solutions with high technological content and provides expertise and services in the areas of the Environment, Energy, Defense and High Technology. CNIM manages projects and sells equipment throughout the world. CNIM is backed by a stable family shareholder base that underpins its future development. The Group employs 2,500 staff and had revenues of €539.9 million in 2016, 54.6% of which was from exports. CNIM is listed on the Euronext Paris stock exchange.

Amatsigroup is a company specializing in pharmaceutical development which operates on a portfolio of 300 international clients, pharmaceutical groups and biotechnology companies. Since 2010, Amatsigroup has pursued its strategy of international growth (creation of an entity in the United States followed by two acquisitions in Belgium),

of expansion of its portfolio of services relating to biological drugs and of extension of its operational capacity in pharmaceutical analysis, formulation, galenic development and the manufacture of small production clinical and commercial batches. In 2016, the company achieved revenues of €45 million and had over 350 highly qualified Life Sciences staff. The majority shareholder of Amatsigroup has been Ekkio Capital, alongside the company's management, since the start of 2011.

Founded over 20 years ago by Dr. Philippe Genne, the company's CEO and Chairman, Oncodesign is a biotechnology company that maximizes the pharmaceutical industry's chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment. With its unique experience acquired by working with more than 600 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modeling and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled several promising molecules with substantial therapeutic potential to be targeted, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB. Based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 165 employees and subsidiaries in Canada and the USA.